Unexpected off-targets and paradoxical pathway activation by kinase inhibitors

ACS Chemical Biology

Volumn 10, Issue 1, 2015, Pages 234-245

  Hantschel, Oliver ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CRIZOTINIB; PROTEIN KINASE INHIBITOR; RAF PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); PROTEIN BINDING; PROTEIN KINASE;

CANCER RESISTANCE; CONFORMATIONAL TRANSITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; REVIEW; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG RESISTANCE; ENZYME ACTIVATION; METABOLISM; PROCEDURES; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84921341934     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb500886n     Document Type: Review

References (118)

1. Benjamin, D., Colombi, M., Moroni, C., and Hall, M. N. (2011) Rapamycin passes the torch: A new generation of mTOR inhibitors Nat. Rev. Drug Discovery 10, 868-880
2. Lamontanara, A. J., Gencer, E. B., Kuzyk, O., and Hantschel, O. (2013) Mechanisms of resistance to BCR-ABL and other kinase inhibitors Biochim. Biophys. Acta 1834, 1449-1459
3. Mullard, A. (2014) 2013 FDA drug approvals Nat. Rev. Drug Discovery 13, 85-89
4. Mullard, A. (2013) 2012 FDA drug approvals Nat. Rev. Drug Discovery 12, 87-90
5. Hantschel, O., Rix, U., and Superti-Furga, G. (2008) Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib Leuk. Lymphoma 49, 615-619
6. Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., and Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29, 1046-1051
7. Fedorov, O., Müller, S., and Knapp, S. (2010) The (un)targeted cancer kinome Nat. Chem. Biol. 6, 166-169
8. Knapp, S., Arruda, P., Blagg, J., Burley, S., Drewry, D. H., Edwards, A., Fabbro, D., Gillespie, P., Gray, N. S., Kuster, B., Lackey, K. E., Mazzafera, P., Tomkinson, N. C. O., Willson, T. M., Workman, P., and Zuercher, W. J. (2013) A public-private partnership to unlock the untargeted kinome Nat. Chem. Biol. 9, 3-6
9. Levitzki, A. (2013) Tyrosine kinase inhibitors: Views of selectivity, sensitivity, and clinical performance Annu. Rev. Pharmacol. Toxicol. 53, 161-185
10. Wheeler, D. L., Dunn, E. F., and Harari, P. M. (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat. Rev. Clin. Oncol. 7, 493-507
11. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293, 876-880
12. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., and Varmus, H. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2, e73
13. Weisberg, E., Manley, P. W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A. L., Mestan, J., Daley, G. Q., Callahan, L., Catley, L., Cavazza, C., Mohammed, A., Neuberg, D., Wright, R. D., Gilliland, D. G., and Griffin, J. D. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7, 129-141
14. Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., and Sawyers, C. L. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305, 399-401
15. Golas, J. M., Arndt, K., Etienne, C., Lucas, J., Nardin, D., Gibbons, J., Frost, P., Ye, F., Boschelli, D. H., and Boschelli, F. (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice Cancer Res. 63, 375-381
16. OHare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., Metcalf, C. A., Tyner, J. W., Loriaux, M. M., Corbin, A. S., Wardwell, S., Ning, Y., Keats, J. A., Wang, Y., Sundaramoorthi, R., Thomas, M., Zhou, D., Snodgrass, J., Commodore, L., Sawyer, T. K., Dalgarno, D. C., Deininger, M. W. N., Druker, B. J., and Clackson, T. (2009) AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 16, 401-412
17. Hantschel, O., Grebien, F., and Superti-Furga, G. (2012) The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL Cancer Res. 72, 4890-4895
18. Shaw, A. T., Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., Solomon, B. J., Wolf, J., Thomas, M., Schuler, M., Liu, G., Santoro, A., Lau, Y. Y., Goldwasser, M., Boral, A. L., and Engelman, J. A. (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer N. Engl. J. Med. 370, 1189-1197
19. Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., Kudchadkar, R., Burris, H. A., 3rd, Falchook, G., Algazi, A., Lewis, K., Long, G. V., Puzanov, I., Lebowitz, P., Singh, A., Little, S., Sun, P., Allred, A., Ouellet, D., Kim, K. B., Patel, K., and Weber, J. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N. Engl. J. Med. 367, 1694-1703
20. Azam, M., Latek, R. R., and Daley, G. Q. (2003) Mechanisms of autoinhibition and STI-571/Imatinib resistance revealed by mutagenesis of BCR-ABL Cell 112, 831-843
21. Kasap, C., Elemento, O., and Kapoor, T. M. (2014) DrugTargetSeqR: A genomics- and CRISPR-Cas9-based method to analyze drug targets Nat. Chem. Biol. 10, 626-628
22. Evan, G. (2008) The future of cancer therapy: an interview with Gerard Evan Dis Model Mech 1, 90-93
23. Gazit, A., Yaish, P., Gilon, C., and Levitzki, A. (1989) Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors J. Med. Chem. 32, 2344-2352
24. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 25, 1035-1044
25. Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., Kocher, T., and Superti-Furga, G. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non-kinase targets Blood 110, 4055-4063
26. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B. J., and Lydon, N. B. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res. 56, 100-104
27. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344, 1031-1037
28. Shah, N. P., Kantarjian, H. M., Kim, D. W., Rea, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., Khoroshko, N., Paquette, R. L., Deininger, M., Collins, R. H., Otero, I., Hughes, T., Bleickardt, E., Strauss, L., Francis, S., and Hochhaus, A. (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia J. Clin. Oncol. 26, 3204-3212
29. Le Coutre, P., Rea, D., Abruzzese, E., Dombret, H., Trawinska, M. M., Herndlhofer, S., Dörken, B., and Valent, P. (2011) Severe peripheral arterial disease during nilotinib therapy J. Natl. Cancer Inst. 103, 1347-1348
30. Eswaran, J. and Knapp, S. (2010) Insights into protein kinase regulation and inhibition by large scale structural comparison Biochim. Biophys. Acta 1804, 429-432
31. Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9, 28-39
32. Rix, U. and Superti-Furga, G. (2009) Target profiling of small molecules by chemical proteomics Nat. Chem. Biol. 5, 616-624
33. Drewes, G. (2012) Chemical proteomics in drug discovery Methods Mol. Biol. 803, 15-21
34. Schirle, M., Bantscheff, M., and Kuster, B. (2012) Mass Spectrometry-Based Proteomics in Preclinical Drug Discovery Chem. Biol. 19, 72-84
35. Harding, M. W., Galat, A., Uehling, D. E., and Schreiber, S. L. (1989) A receptor for the immunosuppressant FK506 is a cis-trans -peptidyl-prolyl isomerase Nature 341, 758-760
36. Fabian, M. A., Biggs, W. H., 3rd, Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., Ford, J. M., Galvin, M., Gerlach, J. L., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Insko, M. A., Lai, A. G., Lelias, J. M., Mehta, S. A., Milanov, Z. V., Velasco, A. M., Wodicka, L. M., Patel, H. K., Zarrinkar, P. P., and Lockhart, D. J. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 23, 329-336
37. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., Faraoni, R., Floyd, M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G., Patel, H. K., Pritchard, S., Wodicka, L. M., and Zarrinkar, P. P. (2008) A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26, 127-132
38. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., and Peterson, J. R. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 29, 1039-1045
39. Zhang, C., Habets, G., and Bollag, G. (2011) Interrogating the kinome Nat. Biotechnol. 29, 981-983
40. Remsing Rix, L. L., Rix, U., Colinge, J., Hantschel, O., Bennett, K. L., Stranzl, T., Muller, A., Baumgartner, C., Valent, P., Augustin, M., Till, J. H., and Superti-Furga, G. (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells Leukemia 23, 477-485
41. Becher, I., Savitski, M. M., Savitski, M. F., Hopf, C., Bantscheff, M., and Drewes, G. (2013) Affinity profiling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP ACS Chem. Biol. 8, 599-607
42. Copeland, R. A., Pompliano, D. L., and Meek, T. D. (2006) Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 5, 730-739
43. Dahl, G. and Akerud, T. (2013) Pharmacokinetics and the drug-target residence time concept Drug Discovery Today 18, 697-707
44. Filippakopoulos, P. and Knapp, S. (2014) Targeting bromodomains: epigenetic readers of lysine acetylation Nat. Rev. Drug Discovery 13, 337-356
45. Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., Taylor, M. J., Johns, C., Chicas, A., Mulloy, J. C., Kogan, S. C., Brown, P., Valent, P., Bradner, J. E., Lowe, S. W., and Vakoc, C. R. (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 478, 524-528
46. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., and Bradner, J. E. (2010) Selective inhibition of BET bromodomains Nature 468, 1067-1073
47. Ciceri, P., Muller, S., OMahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., Martin, S., Wodicka, L. M., Shah, N. P., Treiber, D. K., and Knapp, S. (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology Nat. Chem. Biol. 10, 305-312
48. Ember, S. W., Zhu, J. Y., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., and Schonbrunn, E. (2014) Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors ACS Chem. Biol. 9, 1160-1171
49. Zhou, T., Georgeon, S., Moser, R., Moore, D. J., Caflisch, A., and Hantschel, O. (2014) Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) Leukemia 28, 404-407
50. Shaw, A. T., Yasothan, U., and Kirkpatrick, P. (2011) Crizotinib Nat. Rev. Drug Discovery 10, 897-898
51. Huber, K. V. M, Salah, E., Radic, B., Gridling, M., Elkins, J. M., Stukalov, A., Jemth, A.-S., Göktürk, C., Sanjiv, K., Strömberg, K., Pham, T., Berglund, U. W., Colinge, J., Bennett, K. L., Loizou, J. I., Helleday, T., Knapp, S., and Superti-Furga, G. (2014) Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy Nature 508, 222-227
52. Gad, H., Koolmeister, T., Jemth, A. S., Eshtad, S., Jacques, S. A., Strom, C. E., Svensson, L. M., Schultz, N., Lundback, T., Einarsdottir, B. O., Saleh, A., Gokturk, C., Baranczewski, P., Svensson, R., Berntsson, R. P., Gustafsson, R., Stromberg, K., Sanjiv, K., Jacques-Cordonnier, M. C., Desroses, M., Gustavsson, A. L., Olofsson, R., Johansson, F., Homan, E. J., Loseva, O., Brautigam, L., Johansson, L., Hoglund, A., Hagenkort, A., Pham, T., Altun, M., Gaugaz, F. Z., Vikingsson, S., Evers, B., Henriksson, M., Vallin, K. S., Wallner, O. A., Hammarstrom, L. G., Wiita, E., Almlof, I., Kalderen, C., Axelsson, H., Djureinovic, T., Puigvert, J. C., Haggblad, M., Jeppsson, F., Martens, U., Lundin, C., Lundgren, B., Granelli, I., Jensen, A. J., Artursson, P., Nilsson, J. A., Stenmark, P., Scobie, M., Berglund, U. W., and Helleday, T. (2014) MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool Nature 508, 215-221
53. Celli, C. M., Tran, N., Knox, R., and Jaiswal, A. K. (2006) NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs Biochem. Pharmacol. 72, 366-376
54. Winger, J. A., Hantschel, O., Superti-Furga, G., and Kuriyan, J. (2009) The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2) BMC Struct. Biol. 9, 7
55. Atwell, S., Adams, J. M., Badger, J., Buchanan, M. D., Feil, I. K., Froning, K. J., Gao, X., Hendle, J., Keegan, K., Leon, B. C., Muller-Dieckmann, H. J., Nienaber, V. L., Noland, B. W., Post, K., Rajashankar, K. R., Ramos, A., Russell, M., Burley, S. K., and Buchanan, S. G. (2004) A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase J. Biol. Chem. 279, 55827-55832
56. Chaikuad, A., E, M. C. T., Zimmer, J., Liang, Y., Gray, N. S., Tarsounas, M., and Knapp, S. (2014) A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics Nat. Chem. Biol. 10, 853-860
57. Duan, Y., Chen, L., Chen, Y., and Fan, X. G. (2014) c-Src Binds to the Cancer Drug Ruxolitinib with an Active Conformation PLoS One 9, e106225
58. Hantschel, O., Rix, U., Schmidt, U., Burckstummer, T., Kneidinger, M., Schutze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., and Superti-Furga, G. (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib Proc. Natl. Acad. Sci. U.S.A. 104, 13283-13288
59. Chao, L. H., Stratton, M. M., Lee, I.-H., Rosenberg, O. S., Levitz, J., Mandell, D. J., Kortemme, T., Groves, J. T., Schulman, H., and Kuriyan, J. (2011) A mechanism for tunable autoinhibition in the structure of a human Ca(2+)/calmodulin-dependent kinase II holoenzyme Cell 146, 732-745
60. Littlefield, P., Moasser, M. M., and Jura, N. (2014) An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase Chem. Biol. 21, 453-458
61. Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A. L., Wright, G., Xiao, W., Powell, J., Jiang, J.-k., Thomas, C. J., Rosenwald, A., Ott, G., Muller-Hermelink, H. K., Gascoyne, R. D., Connors, J. M., Johnson, N. A., Rimsza, L. M., Campo, E., Jaffe, E. S., Wilson, W. H., Delabie, J., Smeland, E. B., Fisher, R. I., Braziel, R. M., Tubbs, R. R., Cook, J. R., Weisenburger, D. D., Chan, W. C., Pierce, S. K., and Staudt, L. M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 463, 88-92
62. Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., Young, R. M., Zhao, H., Yang, Y., Xu, W., Buggy, J. J., Balasubramanian, S., Mathews, L. A., Shinn, P., Guha, R., Ferrer, M., Thomas, C., Waldmann, T. A., and Staudt, L. M. (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma Cancer Cell 21, 723-737
63. Woyach, J. A., Johnson, A. J., and Byrd, J. C. (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL Blood 120, 1175-1184
64. Pan, Z., Scheerens, H., Li, S. J., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., Mendonca, R. V., Sweeney, M. D., Scott, K. C., Grothaus, P. G., Jeffery, D. A., Spoerke, J. M., Honigberg, L. A., Young, P. R., Dalrymple, S. A., and Palmer, J. T. (2007) Discovery of selective irreversible inhibitors for Brutons tyrosine kinase ChemMedChem. 2, 58-61
65. Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., and Gray, N. S. (2013) Developing irreversible inhibitors of the protein kinase cysteinome Chem. Biol. 20, 146-159
66. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289, 1938-1942
67. Huse, M. and Kuriyan, J. (2002) The conformational plasticity of protein kinases Cell 109, 275-282
68. Filippakopoulos, P., Kofler, M., Hantschel, O., Gish, G. D., Grebien, F., Salah, E., Neudecker, P., Kay, L. E., Turk, B. E., Superti-Furga, G., Pawson, T., and Knapp, S. (2008) Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation Cell 134, 793-803
69. Lamontanara, A. J., Georgeon, S., Tria, G., Svergun, D. I., and Hantschel, O. (2014) The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility Nat. Commun. 5, 5470
70. Andraos, R., Qian, Z., Bonenfant, D., Rubert, J., Vangrevelinghe, E., Scheufler, C., Marque, F., Regnier, C. H., De Pover, A., Ryckelynck, H., Bhagwat, N., Koppikar, P., Goel, A., Wyder, L., Tavares, G., Baffert, F., Pissot-Soldermann, C., Manley, P. W., Gaul, C., Voshol, H., Levine, R. L., Sellers, W. R., Hofmann, F., and Radimerski, T. (2012) Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent Cancer Discovery 2, 512-523
71. Okuzumi, T., Fiedler, D., Zhang, C., Gray, D. C., Aizenstein, B., Hoffman, R., and Shokat, K. M. (2009) Inhibitor hijacking of Akt activation Nat. Chem. Biol. 5, 484-493
72. Skora, L., Mestan, J., Fabbro, D., Jahnke, W., and Grzesiek, S. (2013) NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors Proc. Natl. Acad. Sci. U. S. A. 110, E4437-4445
73. Brehme, M., Hantschel, O., Colinge, J., Kaupe, I., Planyavsky, M., Kocher, T., Mechtler, K., Bennett, K. L., and Superti-Furga, G. (2009) Charting the molecular network of the drug target Bcr-Abl Proc. Natl. Acad. Sci. U.S.A. 106, 7414-7419
74. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. (2002) Mutations of the BRAF gene in human cancer Nature 417, 949-954
75. Wan, P. T., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Jones, C. M., Marshall, C. J., Springer, C. J., Barford, D., and Marais, R. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116, 855-867
76. Dhomen, N., Reis-Filho, J. S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., and Marais, R. (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice Cancer Cell 15, 294-303
77. Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., and Hirth, P. (2012) Vemurafenib: The first drug approved for BRAF-mutant cancer Nat. Rev. Drug Discovery 11, 873-886
78. Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., Macconaill, L. E., Hahn, W. C., Meyerson, M., and Garraway, L. A. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J. Clin. Oncol. 29, 3085-3096
79. Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., and Marais, R. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140, 209-221
80. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., Morales, T., Aliagas, I., Liu, B., Sideris, S., Hoeflich, K. P., Jaiswal, B. S., Seshagiri, S., Koeppen, H., Belvin, M., Friedman, L. S., and Malek, S. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464, 431-435
81. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., and Rosen, N. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464, 427-430
82. Brennan, D. F., Dar, A. C., Hertz, N. T., Chao, W. C., Burlingame, A. L., Shokat, K. M., and Barford, D. (2011) A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK Nature 472, 366-369
83. Rajakulendran, T., Sahmi, M., Lefrançois, M., Sicheri, F., and Therrien, M. (2009) A dimerization-dependent mechanism drives RAF catalytic activation Nature 461, 542-545
84. Hu, J., Stites, E. C., Yu, H., Germino, E. A., Meharena, H. S., Stork, P. J. S., Kornev, A. P., Taylor, S. S., and Shaw, A. S. (2013) Allosteric activation of functionally asymmetric RAF kinase dimers Cell 154, 1036-1046
85. Rebocho, A. P. and Marais, R. (2013) ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers Oncogene 32, 3207-3212
86. Haling, J. R., Sudhamsu, J., Yen, I., Sideris, S., Sandoval, W., Phung, W., Bravo, B. J., Giannetti, A. M., Peck, A., Masselot, A., Morales, T., Smith, D., Brandhuber, B. J., Hymowitz, S. G., and Malek, S. (2014) Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling Cancer Cell 26, 402-413
87. Lavoie, H., Thevakumaran, N., Gavory, G., Li, J. J., Padeganeh, A., Guiral, S., Duchaine, J., Mao, D. Y. L., Bouvier, M., Sicheri, F., and Therrien, M. (2013) Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization Nat. Chem. Biol. 9, 428-436
88. Freeman, A. K., Ritt, D. A., and Morrison, D. K. (2013) Effects of raf dimerization and its inhibition on normal and disease-associated raf signaling Mol. Cell 49, 751-758
89. Zhao, Y. and Adjei, A. A. (2014) The clinical development of MEK inhibitors Nat. Rev. Clin. Oncol. 11, 385-400
90. Zhang, X., Gureasko, J., Shen, K., Cole, P. A., and Kuriyan, J. (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125, 1137-1149
91. Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., and Kuriyan, J. (2011) Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms Mol. Cell 42, 9-22
92. Zeqiraj, E., Filippi, B. M., Deak, M., Alessi, D. R., and van Aalten, D. M. (2009) Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation Science 326, 1707-1711
93. Zeqiraj, E. and van Aalten, D. M. F. (2010) Pseudokinases-remnants of evolution or key allosteric regulators? Curr. Opin. Struct. Biol. 20, 772-781
94. Stark, G. R. and Darnell, J. E. (2012) The JAK-STAT pathway at twenty Immunity 36, 503-514
95. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., and Skoda, R. C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders N. Engl. J. Med. 352, 1779-1790
96. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., Adelsperger, J., Koo, S., Lee, J. C., Gabriel, S., Mercher, T., DAndrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R. A., Tefferi, A., Griffin, J. D., Eck, M. J., Sellers, W. R., Meyerson, M., Golub, T. R., Lee, S. J., and Gilliland, D. G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7, 387-397
97. Tiedt, R., Hao-Shen, H., Sobas, M. A., Looser, R., Dirnhofer, S., Schwaller, J., and Skoda, R. C. (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice Blood 111, 3931-3940
98. Mesa, R. A., Yasothan, U., and Kirkpatrick, P. (2012) Ruxolitinib Nat. Rev. Drug Discovery 11, 103-104
99. Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Jr., Arcasoy, M. O., Hexner, E., Lyons, R. M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I. L., Sun, W., Sandor, V., and Kantarjian, H. M. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N. Engl. J. Med. 366, 799-807
100. Harrison, C., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A. M., Barbui, T., and Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N. Engl. J. Med. 366, 787-798
101. Pardanani, A. (2012) Ruxolitinib for myelofibrosis therapy: Current context, pros, and cons Leukemia 26, 1449-1451
102. Hantschel, O., Warsch, W., Eckelhart, E., Kaupe, I., Grebien, F., Wagner, K.-U., Superti-Furga, G., and Sexl, V. (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia Nat. Chem. Biol. 8, 285-293
103. Zhang, Q., Zhang, Y., Diamond, S., Boer, J., Harris, J. J., Li, Y., Rupar, M., Behshad, E., Gardiner, C., Collier, P., Liu, P., Burn, T., Wynn, R., Hollis, G., and Yeleswaram, S. (2014) The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: A putative mechanism for the onset of Wernickes encephalopathy Drug Metab. Dispos. 42, 1656-1662
104. Grundschober, E., Hoelbl-Kovacic, A., Bhagwat, N., Kovacic, B., Scheicher, R., Eckelhart, E., Kollmann, K., Keller, M., Grebien, F., Wagner, K. U., Levine, R. L., and Sexl, V. (2014) Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2 Leukemia 28, 1918-1922
105. Akada, H., Akada, S., Hutchison, R. E., Sakamoto, K., Wagner, K.-U., and Mohi, G. (2014) Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells Stem Cells 32, 1878-1889
106. Grisouard, J., Hao-Shen, H., Dirnhofer, S., Wagner, K.-U., and Skoda, R. C. (2014) Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia Haematologica 99, e52-54
107. Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O. N., Xu, C.-F., Neubert, T. A., Skoda, R. C., Hubbard, S. R., and Silvennoinen, O. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling Nat. Struct. Mol. Biol. 18, 971-976
108. Bandaranayake, R. M., Ungureanu, D., Shan, Y., Shaw, D. E., Silvennoinen, O., and Hubbard, S. R. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F Nat. Struct. Mol. Biol. 19, 754-759
109. Lupardus, P. J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A. R., and Eigenbrot, C. (2014) Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition Proc. Natl. Acad. Sci. U.S.A. 111, 8025-8030
110. Shan, Y., Gnanasambandan, K., Ungureanu, D., Kim, E. T., Hammarén, H., Yamashita, K., Silvennoinen, O., Shaw, D. E., and Hubbard, S. R. (2014) Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase Nat. Struct. Mol. Biol. 21, 579-584
111. Knight, Z. A., Lin, H., and Shokat, K. M. (2010) Targeting the cancer kinome through polypharmacology Nat. Rev. Cancer 10, 130-137
112. Sharma, S. V., Haber, D. A., and Settleman, J. (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents Nat. Rev. Cancer 10, 241-253
113. Holohan, C., Van Schaeybroeck, S., Longley, D. B., and Johnston, P. G. (2013) Cancer drug resistance: An evolving paradigm Nat. Rev. Cancer 13, 714-726
114. Winter, G. E., Rix, U., Carlson, S. M., Gleixner, K. V., Grebien, F., Gridling, M., Muller, A. C., Breitwieser, F. P., Bilban, M., Colinge, J., Valent, P., Bennett, K. L., White, F. M., and Superti-Furga, G. (2012) Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML Nat. Chem. Biol. 8, 905-912
115. Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., and Knight, Z. A. (2008) Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases Nat. Chem. Biol. 4, 691-699
116. Miduturu, C. V., Deng, X., Kwiatkowski, N., Yang, W., Brault, L., Filippakopoulos, P., Chung, E., Yang, Q., Schwaller, J., Knapp, S., King, R. W., Lee, J.-D., Herrgard, S., Zarrinkar, P., and Gray, N. S. (2011) High-throughput kinase profiling: A more efficient approach toward the discovery of new kinase inhibitors Chem. Biol. 18, 868-879
117. Lin, Y.-L., Meng, Y., Jiang, W., and Roux, B. (2013) Explaining why Gleevec is a specific and potent inhibitor of Abl kinase Proc. Natl. Acad. Sci. U.S.A. 110, 1664-1669
118. Zhao, H., Huang, D., and Caflisch, A. (2012) Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics ChemMedChem 7, 1983-1990